Medrx Co

Medrx Co Equity Ratio

The Equity Ratio of Medrx Co (4586.T) as of Nov 3, 2026 is 94.97 %. In the previous year, Equity Ratio was 95.30 % — a change of -0.34% (lower).

Equity Ratio

94.97 %

YoY

-0.34%

Last updated:

Equity Ratio of Medrx Co is 2025 94.97 % . Equity Ratio of Medrx Co was 2024 95.30 % . It decreases by -0.34% lower compared to the previous year.

The Medrx Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
92.18 JPY
Jan 1, 2019
93.81 JPY
Jan 1, 2020
93.48 JPY
Jan 1, 2021
92.74 JPY
Jan 1, 2022
86.73 JPY
Jan 1, 2023
93.71 JPY
Jan 1, 2024
95.30 JPY
Jan 1, 2025
94.97 JPY
The Medrx Co Equity Ratio history
YEAREquity RatioYoY
94.97 %-0.34%
95.30 %+1.69%
93.71 %+8.05%
86.73 %-6.48%
92.74 %-0.79%
93.48 %-0.35%
93.81 %+1.77%
92.18 %-3.34%
95.36 %+17.14%
81.40 %-12.57%
93.10 %-2.37%
95.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Equity Ratio of Medrx Co is 94.97 % in 2025.

Equity Ratio of Medrx Co changed from 95.30 % to 94.97 %, representing a -0.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Medrx Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Medrx Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Medrx Co

All Key Metrics — Medrx Co